Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck On Track To File Novel Sleep Aid Suvorexant In 2012

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Merck announced its potential first-in-class dual orexin receptor antagonist suvorexant successfully completed a second Phase III trial, apparently without safety concerns that led Actelion/GlaxoSmithKline to drop their DORA almorexant a year ago on Phase III results.


Related Content

For Merck, Outcomes Trials Offer Fast Track To Payers
For Merck, Outcomes Trials Offer Fast Track To Payers
Merck CEO To Street: Watch For Short-term Adaptability, Long-Term Innovation
Merck Enters The Alzheimer’s Disease Race, Plans Filings For Five New Drugs
Actelion, GSK Scrap Sleep Drug Almorexant
Insomnia Market Snapshot: Generics May Keep Drug Makers Up At Night
Schering Plans Bridion Clinical Trial To Address FDA’s Hypersensitivity Concerns


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts